Core Viewpoint - The acquisition of 100% equity in Shanghai Guanhua Medical Technology Co., Ltd. by Fangda Holdings aims to enhance the group's global laboratory service capabilities and strengthen its influence in China [1][2] Group 1: Acquisition Details - Fangda Holdings' wholly-owned subsidiary, Fangda Shanghai, plans to acquire Shanghai Guanhua Medical Technology for a total consideration of RMB 270 million [1] - The target company specializes in clinical trial technology services, related services, and laboratory services [1] Group 2: Strategic Objectives - The acquisition is intended to expand the group's central laboratory services in China and enhance its influence in the Asia-Pacific region [1] - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas, known for its compliance with Good Clinical Practice (GCP) and internationally recognized services [1][2] Group 3: Synergy and Market Position - The target group's strong track record, including its role in the successful launch of 35 new drugs and support for regulatory audits, complements the existing expertise of the group [2] - The acquisition will enhance the group's ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions, further solidifying its position as a trusted partner in the clinical research industry [2]